The FDA’s decision to grant accelerated approval for the anti-Alzheimer’s drug lecanemab, which will be sold as Leqembi, has significant potential for research into treatment of the disease. But people living with Alzheimer’s and their families will face difficult choices once the drug is made available later this month by Biogen and the Japanese firm Eisai. A trial found the [...]
What should people living with dementia and their families take away from the recent data published on lecanemab, the Alzheimer’s drug developed by Biogen and the Japanese firm Eisai? The drugmakers’ announcement of their Phase 3 trial results got lots of attention in the popular press. Some stories heralded the drug as a “breakthough.” But even experts disagree about the [...]
In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial. In bureaucratic language: “Monoclonal antibodies directed against amyloid for the treatment of [Alzheimer’s Disease] provided outside of the CMS approved randomized controlled trials and trials supported [...]